An Exploratory Study Assessing the Short Term Predictors of Remission of Voclosporin 23.7mg BID in Combination With Standard of Care in Patients With Active Lupus Nephritis

Trial Profile

An Exploratory Study Assessing the Short Term Predictors of Remission of Voclosporin 23.7mg BID in Combination With Standard of Care in Patients With Active Lupus Nephritis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Voclosporin (Primary) ; Corticosteroids; Mycophenolate mofetil
  • Indications Lupus nephritis
  • Focus Biomarker; Proof of concept; Therapeutic Use
  • Acronyms AURION
  • Sponsors Aurinia Pharmaceuticals
  • Most Recent Events

    • 27 Mar 2017 Results at week 48 published in an Aurinia Pharmaceuticals media release.
    • 27 Mar 2017 Results at 48 weeks presented at the 12th International Congress on Systemic Lupus Erythematosus and 7th Asian Congress on Autoimmunity, according to an Aurinia Pharmaceuticals media release.
    • 17 Mar 2017 Planned End Date changed from 1 Jan 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top